Drug and Medication Industry: Technische Universitat Munchen – Developmental Therapeutics Review – Q4 2010

• Publication date: December 2010

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by G...

The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Technische Universitat Munchen - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Technische Universitat Munchen human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Technische Universitat Munchen with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Technische Universitat Munchen’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Technische Universitat Munchen’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Technische Universitat Munchen in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Technische Universitat Munchen’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Technische Universitat Munchen.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Technische Universitat Munchen and identify potential opportunities in those areas.

Global Therapy Industry

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Technische Universitat Munchen Snapshot 5
Key Information 5
Key Facts 5
Technische Universitat Munchen – Research and Development Overview 6
Key Therapeutic Areas 6
Technische Universitat Munchen – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
Technische Universitat Munchen – Pipeline Products Glance 12
Technische Universitat Munchen – Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Technische Universitat Munchen Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 15
Technische Universitat Munchen – Drug Profiles 16
Letrozole 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
cetuximab + fluorouracil + oxaliplatin 17
Product Description 17
Mechanism of Action 17
R&D Progress 18
Cetuximab + Oxaliplatin + Fluorouracil + Radiation Therapy 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Everolimus 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gemcitabine + Oxaliplatin + Radiation Therapy 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Glivec 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Nilotinib + Everolimus 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Rituximab + Cyclophosphamide + Fludarabine Phosphate 26
Product Description 26
Mechanism of Action 26
R&D Progress 27
Rituximab for Transplantation (Technische Universitat Munchen) 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Trastuzumab + Anastrozole + Cyclophosphamide + Docetaxel + Epirubicin Hydrochloride + Goserelin + Tamoxifen Citrate + Radiation Therapy 29
Product Description 29
Mechanism of Action 30
R&D Progress 31
Vigil 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Imatinib + Capecitabine + Cisplatin 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Technische Universitat Munchen – Pipeline Analysis 35
Technische Universitat Munchen – Pipeline Products by Therapeutic Class 35
Technische Universitat Munchen Pipeline Products By Target 37
Technische Universitat Munchen – Pipeline Products by Route of Administration 39
Technische Universitat Munchen – Pipeline Products by Molecule Type 40
Technische Universitat Munchen – Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 43
Contact Us 43
Disclaimer 43List of Tables
Technische Universitat Munchen – Pipeline by Therapy Area and Indication, 2010 7
Technische Universitat Munchen – Pipeline by Stage of Development, 2010 9
Technische Universitat Munchen – Monotherapy Products in Pipeline, 2010 10
Technische Universitat Munchen – Combination Treatment Modalities in Pipeline, 2010 11
Technische Universitat Munchen – Phase III, 2010 12
Technische Universitat Munchen - Phase II, 2010 13
Technische Universitat Munchen - Phase I, 2010 15
Technische Universitat Munchen - Pipeline By Therapeutic Class, 2010 35
Technische Universitat Munchen - Pipeline By Target, 2010 37
Technische Universitat Munchen – Pipeline By Route of Administration, 2010 39
Technische Universitat Munchen – Pipeline By Molecule Type, 2010 40

List of Figures
Technische Universitat Munchen – Pipeline by Therapy Area and Indication, 2010 7
Technische Universitat Munchen – Pipeline by Stage of Development, 2010 9
Technische Universitat Munchen – Monotherapy Products in Pipeline, 2010 10
Technische Universitat Munchen – Combination Treatment Modalities in Pipeline, 2010 11
Technische Universitat Munchen – Pipeline By Therapeutic Class, 2010 35
Technische Universitat Munchen - Pipeline By Target, 2010 37
Technische Universitat Munchen – Pipeline By Route of Administration, 2010 39
Technische Universitat Munchen – Pipeline By Molecule Type, 2010 40